Fosamax, manufactured by Merck, is a prescription drug that is used to treat osteoporosis and Pagets disease. Fosamax was approved by the FDA in 1995 has been taken by some twenty million patients. This drug is a member of the bisphosphonate class of drugs and works by altering bone recycling processes by inhibiting bone breakdown.

Fosamax Therapy is Linked to Bone Damage:

Although Fosamax is meant to strengthen bone for individuals who are losing bone mass, it has been linked to osteonecrosis of the jaw (ONJ) and femur fractures. In September 2010, the American Society of Bone and Mineral Research released a study that provides a link between femur fractures and bisphosphonates such as Fosamax. The study looked at 310 cases of rare femur fractures and found that in 291 cases the patients had been taking bisphosphonates. It has been suggested that bisphosphonate drug labels should be changed to alert patients and healthcare providers of the femur fracture risk associated with long-term use of Fosamax and related generics. The FDA is currently considering these recommendations. These fosamax injuries have initiated a number of Fosamax lawsuits.

Fosamax Health Risks and Side effects:

One of the most common side effects of Fosamax therapy is stomach pain. Less common side effects indicating fosamax injuries include:

First occurrence or worsening of heartburn
Chest pain
Difficulty swallowing
Vomiting (bloody or coffee ground type)
Bloody or black stools
Mouth sores
Hives
Itching
Swelling of the face, lips or tongue
Difficulty breathing
Eye pain
Flu-like symptoms
Irritation of the esophagus or ulcerations
Muscle/joint pain

Other side effects reported include:

Nausea
Headache
Change in taste
Gas
Bloating
Diarrhea
Constipation

You should report these side effects to your healthcare provider.

If you are thinking of taking Fosamax therapy there are certain things you should discuss with your healthcare provider. Let your doctor know if you have any allergies to Fosamax or other allergies to foods, preservatives or dyes. Also report any digestion, throat, intestine, kidney or stomach problems you may have as Fosamax may worsen these conditions. It is important that you can sit or stand upright for at least thirty minutes after taking Fosamax. If you cant, it is possible for this drug to cause severe throat damage. It is also important that you have a proper diet and maintain healthy levels of calcium and vitamin D.

If you have experienced an unusual femur fracture, osteonecrosis of the jaw (ONJ), or any of the serious fosamax injuries listed above while on Fosamax therapy you may be entitled to financial compensation for pain and suffering, lost wages and medical expenses. Fosamax Lawsuits are currently being filed across the country.

About the Author:
Susan Ardizzoni, Ph.D. holds a Doctorate in Biology with a major in Neuroscience (medical) and minors in Biochemistry, Physics, and Mathematics with experience in basic and clinical research. Although the author is not an attorney, this article was sponsored by the law firm of Bernstein Liebhard LLP and constitutes Attorney Advertising. To learn more about Fosamax injuries or

kinase inhibitor is the recent popular molecule that catches the attention of the researchers. Companies in the research and development field of this industry are doing their research on the basis of their feasible studies. They try to get the exact dosage of each molecule for any specific drug. They try to find out the exact and maximum level of such molecules that can be protein kinase inhibitors which is an important component for cancer related drugs. Even such advanced companies are providing constant aid of various complications. A biotech and pharmaceutical company possesses various responsibilities including analytical study, physical and chemical characterization. They do their best in this job with the help of advanced laser technology, Nanotechnology, evaluation of devices. The developers are always very busy to pursuit for a new invention with effective technologies. They try to focus on the new expansion and invention just to provide more and more aids. With such serious and expertise team the industry is really getting the benefits in the form of innovative invention to solve the complication.

The research and development companies in the pharmaceutical industry run various unique pharmaceutical product development programs. Recently the focus is on the tyrosine kinase inhibitors to try to evaluate its effects that can solve incurable complications. Such growing companies try to verify the status of such components for the maximum utilization in the betterment of the mankind with a large-scale infrastructure, committed project teams, cross-functional therapeutic units and new technologies. Such companies basically focus on the discovery, improvement and post-approval pharmaceutical product services along with the worldwide dedication to quality and delivering strategic solutions for compound. The scientists and the researchers are constantly assisting customers in the development of new products and line extensions. With such an active service and expertise the companies can maximize returns on their research and investments and speed up the release of safe and effective therapeutics to patients. Discovery and progress are the two parts of the entire industry. The researchers of the industry are constantly trying to bring out innovative chemical and biological entities. The enlargement part of this industry comprises chemical, biological and pharmaceutical expansion, drug security and metabolism, clinical research and progress, and medical dealings.

About the Author:
http://www.synkinase.com publishes this post so that you can get a clear idea about the research and development sector of the biotech and pharmaceutical industry.

A microbiology lab is the main place of work of any microbiologist that’s not from that particular field. It is a very clean and sterile environment where supplies along with the equipment for testing and culturing of microorganism samples are executed, along with research. Numerous laboratories are specialized, which suggests, they may be occupied with a certain sub-discipline of microbiology. Microbiology is linked with medicinal, veterinary, environmental, industrial, food, pharmaceutical or agricultural applications.

Medical microbiology is probably the most well-known branch of microbiology. Hospital labs often have a clinical microbiology unit, which usually gets any kind of clinical specimen. Such as instance swabs, feces, urine, blood, sputum, cerebrospinal fluid, synovial fluid, and infected tissue. The project here is generally looking for suspected pathogens and also determining them, along with testing to figure out if your revealed pathogen is actually sensitive or perhaps resistant against a new recommended medication. The result is usually a report pinpointing the disease-causing organism plus the sort and dosage of medications that needs to be provided to the individual.

A hospital microbiology lab may additionally worry about parasites and viruses. Blood work is also performed here, wherein, using whole blood specimens, full blood counts and blood tests are done and the outcomes reviewed. On occasion, blood samples will be citrated to investigate blood clotting times and coagulation factors.

Microbiology provides plenty of practical applications, besides within hospitals as well as clinics. There are actually organizations that offer microbiological testing with regard to medical devices to ensure that the product fulfills federal government criteria along with confirming the product promises. Assessments cover facility validation, natural materials testing, sterilization and packaging validations, biocompatibility, reusable device studies and scheduled quality control assessments. These tests may help manufacturers of medical devices manage to get their goods to sell faster and at a lower risk.

Plenty of microbiologists are employed in the pharmaceutical sector. Medications, drugs as well as health supplements are generally formulated and researched thoroughly inside of a microbiology lab. Checks incorporate container integrity experiments, disinfectant reports, preservative effectiveness, scientific studies, antibiotic effectiveness assays, sterilization and also packaging validations as scheduled quality control checks. Third party evaluators can perform even more tests for instance filter validations, facility validations and clean room, as well as isolator facilities validation.

The food business hires microbiologists in product development and quality control. When creating a food product, shelf life is a vital characteristic. Foodstuff that goes bad easily can be hard to promote, therefore microbiologists are generally on hand to aid in produce production and packaging methods to minimize spoilage and extend quality. A few microorganisms are utilized to generate food such as those that produce fermentation. The use of a microbiologist helps in maintaining top quality food throughout production.

Microbiologists help to make significant positive effects in human society each day. For example, their work is the basis of a vast amount of information regarding the health of the individual, pertaining to the diagnosis, treatment and prevention of disease. The microbiological research has also led to numerous medical and scientific breakthroughs that assist and improve living conditions. A microbiology lab may seem like any other biology or chemistry lab, but the job accomplished here has a significant impact on human life.

About the Author:
Microbiology lab tests have to be conducted in a sterile, clean, microbiology testing lab. It is in these labs that scientific breakthroughs can happen, making them an exciting place to work and conduct experiments.

The study offers an overview of the Multiple Sclerosis disease-modifying product market, including regulatory issues, and accompanied by detailed analyses and forecasts by product. MS is an autoimmune disease characterized by the bodys own immune system attacking itself and causing spots of demyelination (plaques) in the brain and spinal cord. Symptoms of MS vary widely depending on the severity of the disease and which nerve cells are attacked. Today there are currently eight disease-modifying therapies for MS approved throughout the world. Biologics represent the largest class of MS disease-modifying therapies by sales and by number of approved therapies accounting for six out of the eight approved MS disease-modifying products (Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri). Of these biologics, five are beta interferon products. All of these approved MS agents are able to slow down the progression of the disease but none can reverse any nerve damage that occurs due to demyelination. ( http://www.bharatbook.com/detail.asp?id=152283&rt=Multiple-Sclerosis-MSDrugs-and-Biologics-Technologies-and-Global-Markets.html )

For each drug or biologic for MS on the market, all agents for MS in mid-to-late stages of clinical development, and some in earlier stages of development we have examined where these compounds stand in the development process, the major challenges to their regulatory approval or market success, their competitive profile, and, if applicable, their projected sales through 2015.

We were particularly interested in profiling small molecule drugs, therapeutic vaccines and other biologics targeting MS that are in Phase II or III clinical studies or those with unique mechanisms of action in earlier stages of development. We identify the leading MS treatments by formulation, by mechanism of action, and by geographic location. In some cases, we discuss notable compounds that failed in clinical testing, such as Roche and Biogen Idecs Rituxan (rituximab), or that were pulled from the market due to adverse event or other issues. We also discuss the potential of some compounds that are being tested for other inflammatory or autoimmune disorders that could in the future potentially be tested as a treatment for or used off-label for MS.

Disease-modifying agents to treat MS are currently one of the largest classes of pharmaceutical products by sales in the U.S. and throughout the world. Sales of these agents for MS have grown from less than $1 billion worldwide in 1999 to more than $10 billion in 2009. A period of dynamic growth in the MS disease-modifying product market is expected to continue with seven new agents with unique mechanisms of action or new formulations entering the market between 2010 and the end of 2015. Longer-acting formulations of existing MS products are also expected to have a positive effect on the market as well.

New approaches to treating MS are being pursued by pharmaceutical and biotech companies as many of them look to move beyond agents such as the interferons that primarily slow the progression of MS. These potential new disease-modifying agents with novel mechanisms of action or improved delivery systems will provide powerful new options for patients failing or intolerable to the currently prescribed treatments for MS.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=152283&rt=Multiple-Sclerosis-MSDrugs-and-Biologics-Technologies-and-Global-Markets.html

Related Reports

Global Multiple Sclerosis Drug Market 2010-2025
http://www.bharatbook.com/detail.asp?id=135347&rt=Global-Multiple-Sclerosis-Drug-Market-2010-2025.html

Multiple Sclerosis Market Forecast
http://www.bharatbook.com/detail.asp?id=130004&rt=Multiple-Sclerosis-Market-Forecast.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook

About the Author:
Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, conferences & seminars, newsletters, and online databases for the past twenty two years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the wo

With the people's living standards and lifestyle changes, the "rich man's disease," said the incidence of diabetes shows rapid rise in violent trend. So far, the global type 2 diabetes have 250 million people, is expected to reach 380 million by 2025 people. Posted in ResearchandMarkets "diabetes market outlook 2011" report: 2005 Global Diabetes drug market has reached 186 billion U.S. dollars, an increase of 11.5% the previous year. In 2006, the global diabetes drug market crossed the 200 billion mark.

Considerable domestic market capacity China, as a large population, rapidly rising incidence of diabetes grim situation alarming. According to relevant statistics, China has reached 3,000 people with diabetes, prevalence rate of about 2% to 4%, and to add 1 million patients per year rate of increase, China has become the world's second largest country in diabetes, 2 the great majority of diabetic patients. In the past 20 years, China's incidence of diabetes increased five times. According to estimates, China's diabetes drug market reached 13 billion yuan, and has become the cardiovascular, Cancer Serious harm to people's health after the third largest disease.

More worrying is that many complications of diabetes can occur, and some direct threat to the lives of patients. Research shows that 10 years after onset diabetes, 30% to 40% of patients at least a complication occurs. According to Shanghai Jiaotong University, Ruijin Hospital, Professor Chen Mingdao introduced in 2006 ADA annual meeting, the scientists concluded the clinical complications of type 2 diabetes include: large vascular disease, cerebrovascular disease (incidence rate 10.2%), cardiovascular disease (incidence rate 25.3%), peripheral vascular disease (incidence rate 10.6%); microvascular complications retinopathy (incidence rate 33.1%), renal disease (incidence rate 20.9%), peripheral neuropathy (incidence 41.5%). Type 2 diabetes the risk of cardiovascular disease and stroke than the general population of 2 to 4 times higher, the patient will be reduced by 5 to 10 years of life. In all diabetes-related deaths, 80% of cardiovascular disease (CVD), and therefore, the medical profession has been active in taking all measures to do its utmost to reduce the risk of type 2 diabetes, cardiovascular factors.

Charming lilac

1918, the pharmacists found that guanidine substances in plants can reduce the urine, and targeting the goat beans (French lilac, Galegaofficinalis, goat'srue) on; in 1922, scientists will be lilac in Ireland components with hypoglycemic effect of metformin for the first time the successful synthesis; in 1957, from Bristol-Myers Squibb (BMS) patent metformin has been approved in France for the first time used as a clinical hypoglycemic drugs, and the name "Glucophage ( Glucophage) ". In the following 50 years, as the first one oral hypoglycemic drug metformin, has become the classic type 2 diabetes medication, and in December 29, 1994 the U.S. FDA approval to market. In 1998, UKPDS landmark study (United Kingdom Prospective Diabetes Study) confirmed the long-term benefits of metformin on cardiovascular protection; in 2002, the EU approved Glucophage for 10 to 16 year-old children with type 2 diabetes. Company BMS ( ) original patent shall expire that year on March 3, 2005 is based on the age of 10 to 16 pediatric patients with type 2 diabetes, clinical studies, FDA will Glucophage ( ) extension of the patent 6 months, this decision is a supplementary new drug application for the drug (SNDA), which was being reviewed. In 2007, China's diabetes, metformin has become the new guidelines the only choice for obese patients with oral hypoglycemic drugs.

About the Author:
We are high quality suppliers, our products such as 4D Theater System Manufacturer , China 3D Cinema System for oversee buyer. To know more, please visits 4D Theater System.

Do you wish you could know yourself better and feel great and safe in yourself? How great wouldn’t it be to be a winner, a leader and a groundbreaker? Just think about being that person that you want to be, living out the life that you dreamed to live – the life of all your aspirations.

Self hypnosis may be used to simply reprogram the part of your brain that we identify as your sub-conscious mind. This in the end lets you achieve your desired results from life and achieve the lifestyle of your dreams as you go along your journey of self discovery and self development. By altering and challenging your beliefs you’ll actually begin to clear out old and undesirable obstacles that may have held you back up to this time.

One can learn the art of self hypnosis in various ways. You can get a book or seek the help of your local hypnotherapist who ought to be more than willing to instruct you and assist you to develop this new skill into one that you may use effectively. Some hypnotherapists also offer courses and seminars to teach people self hypnosis; on the other hand I invariably believe that it’s best to do your research prior to going on these and you can do that by finding a good book and reading it.

All of us have mental blocks which hinder us from achieving any further success and wealth than we believe we equipped of accomplishing. For example, just think for a second as to how much wealth you desire to make in the coming year. Now, whatever estimate you came up with signifies a block in itself. Why didn’t you dream up a higher figure?

Self hypnosis is able to do your body … your mind… your body… and your business a lot of good. Study well your options!

About the Author:
This self hypnosis goal should be concise and precise. As we now settle into the 21st Century we see more and more uses of hypnosis as a medical tool. In fact you can even program into your unconscious mind the same behaviours as the people who have what you now want. self hypnosis pain

These changes and more are addressed in Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:

Histology/Cytology

Immunoassays

Flow Cytometry

Rapid Tests

Molecular Assays

Tissue Arrays

Circulating Tumor Cells

Pharmacodiagnostics

Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:

Immunoassay Lab Based Cancer Test Sales

Pap Smear Testing Volumes

World Cancer Statistics

POC Tests

DNA Reagents for Cancer Testing

CTC Testing Markets

Biochip Innovations

New Companies with Novel Approaches

“Laggard” Companies Who Have Not Met Expectations

Major Protein and Molecular Markers Used in Tissue Staining

Biomarkers Under Investigation

Acquisitions and Mergers

Status of PGx Testing

Microarray Markets in Clinical Labs

Lists of Vendors and Major Products

Unmet Needs of the Marketplace

This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH As well as tests for specific cancers:

Bladder Cancer

Breast Cancer

Cervical Cancer

Colon Cancer

Lung Cancer

Ovarian Cancer

Prostate Cancer

This latest edition of study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:

Tests for specific cancers, and

Cancer tests in specific IVD segments

This allows the reader to match his or her own situation to the market at large.

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles.

Top Tier Companies

Abbott Diagnostics

Beckman Coulter Inc.

Becton, Dickinson and Company (BD)

bioMerieux Inc.

Bio-Rad Laboratories Inc.

Dako A/S

Fujirebio Diagnostics, Inc.

Gen-Probe Inc.

Hologic, Inc.

Inverness Medical Innovations

Ortho Clinical Diagnostics

QIAGEN N.V.

Roche Diagnostics

Siemens Medical Solutions Diagnostics

Sysmex Corporation

Status Quo Leader Companies

AdnaGen AG

Agendia BV

AMDL Diagnostics, Inc. (ADI)

American Diagnostica Inc.

Aperio Technologies, Inc.

Asuragen, Inc.

AviaraDx

Binding Site (The) Ltd.

BioCurex Inc.

BioGenex Laboratories, Inc.

BioImagene

Bio-Reference Laboratories, Inc.

Biotage AB

bioTheranostics

BioView Ltd.

Celera Diagnostics

China Medical Technologies, Inc.

Cisbio Bioassays

Clarient Inc. (formerly ChromaVision)

Clinical Data, Inc.

CytoCore, Inc.

DxS Ltd.

Epigenomics AG

Genetix Applied Imaging

Genomic Health, Inc.

Genzyme Genetics

Health Discovery Corporation

HistoRx, Inc.

Ikonisys, Inc.

Ipsogen SA

Lab21 Healthcare

Laboratory Corporation of America Holdings (LabCorp)

Life Technologies

Monogram Biosciences, Inc.

mtm laboratories AG

Myriad Genetics, Inc.

Nanosphere, Inc.

OncoVista Innovative Therapies, Inc.

Pathwork Diagnostics

Precision Therapeutics

Prometheus Laboratories Inc.

Quest Diagnostics

Response Genetics, Inc.

Rosetta Genomics Ltd.

Sequenom

Transgenomic Inc.

Veridex, LLC

Vermillion Inc.

Zila, Inc.

New Entrants

20/20 GeneSyst

For more information please visit :

http://www.aarkstore.com/reports/The-Worldwide-Market-for-Cancer-Diagnostics-4th-Edition-12938.html

About the Author:
Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

Author of Chinese medicine preparations exported to Europe market opportunities and challenges facing analyzed, and the corresponding countermeasures and suggestions. Author points out: China Pharmaceutical companies Should seize the global pharmaceutical manufacturing centers to Asia’s opportunities, to overcome its own lack of active participation in international production of pharmaceutical preparations, to achieve industrial upgrading. Change its view with the current state of economic development pattern of the industry is worth serious consideration.

Into the European market, is the current expectations of many domestic pharmaceutical companies, in this context, opportunities and challenges, which requires the industry recognize their own shortcomings and domestic and international environment, enhance the software and hardware development.

Good opportunities facing 1. Generic The expansion of markets to provide opportunities for the export of agents

Recent years, the international pharmaceutical industry will usher in the medical history of a rare concentration of drug patents expire favorable period. Statistics show that in 2008, the global for years Sell Approximately 20 billion U.S. dollars of drug patents expire, the 2011 to 2015, the scale of a further rise to 770 million. With the “blockbuster” drugs in the world-class patent exclusivity period has ended, global sales of generic drugs is expected to amount to 10% ~ 15% rate, far higher than the global pharmaceutical market growth rate.

The development of generic versions of the same U.S. and European governments have also been encouraged. In recent years, forced by population aging intensifies, health care spending surge, European and American developed countries vigorously promote generic drug substitution of the original research plan, hoping to get low-cost global sourcing of pharmaceutical products, which also contributed to the generics market growth. In China, the bulk drugs, intermediates, packaging, equipment and labor are relatively cheap, cost advantage the export of agents, a number of patented medicines in the world, exclusive of the end, the basis has been established generic pharmaceutical industry and this is our country is a great opportunity.

2. National policy support, enterprises motivated

China currently has more than 4,700 pharmaceutical companies to achieve the GMP requirements, the domestic enterprises to international practice cGMP transform a certain foundation. Meanwhile, in the past few decades, China’s pharmaceutical companies have formed a complete set with imitation-based research and development system, production equipment, personnel and technological level has been greatly improved, my copy in generic terms already has a strong international competitiveness. There is some obstacle

And pharmaceutical preparations in China different from traditional export markets, Europe and the United States developed countries by improving intellectual property protection and full, strict market access conditions and fierce competition, and build a high market barriers. This is our country into the European market, pharmaceutical preparations caused some difficulties, primarily in the following areas:

1. Europe and the United States market, the full protection of intellectual property

For the preparation of production, intellectual property protection of pharmaceuticals developed countries in Europe and the United States consists of three parts: the raw material drug production process patent protection, patent protection of drug production and clinical application of patent protection. In the usual sense of the original study drug patent expiration refers to the clinical application of exclusive patent protection expires, generic drugs have the same ingredients are listed on the eligibility of sale. However, the preparation of the production process is usually longer than the clinical application of patent protection, and thus exports when imitation agents still need to avoid infringing the production of bulk drugs and formulation patents.

About the Author:
I am an expert from China Hardware Suppliers, usually analyzes all kind of industries situation, such as circuits assembly , canon camera a80.

SPAWAR (ship and fire identification and mapping) Predictive analytics is demonstrated by the RAPid Image Exploitation Resource (RAPIER) which uses advanced image algorithms to detect, classify and map ships and identify and map fires using high-resolution satellite imagery. It is a valuable tool for first responders, disaster response coordinators, maritime law enforcement, and port authorities.

LinkedIn (social media beta test) — LinkedIn will demo Signal, which provides a new way to consume information and news thats most relevant to professionals. Signal is the first LinkedIn product aimed at helping professionals glean relevant insight from status updates and news. Attendees can experience how their personal LinkedIn profiles create a more effective social search and news search engine, updated to the minute.

Parity Computing (medical text analysis) — Demonstrates provider-facing healthcare analytics products. These clinical decision support products interpret human-written medical text and real-time device data to save lives, reduce costs, and help hospitals assess themselves.

UCSD LISA (driver prediction system) — The Laboratory for Intelligent and Safe Automobiles (LISA) explores innovative approaches to making future automobiles safer and intelligent. Its research considers issues in sensing, analysis, modeling, and prediction of parameters associated with drivers, occupants, vehicle dynamics and vehicle surroundings. . In collaboration with automakers Volkswagen and Nissan, LISA has implemented a next-generation Driver Assistance System which predicts drivers intentions to change lanes, turn, or brake up to 2.5 seconds prior to the maneuver.

Intuit (customer feedback analysis) — Intuit, maker of TurboTax software, demonstrates how it applies text analytics to large amounts of unstructured customer feedback (literally the voice of the customer) to enable improvements in product, infrastructure, and support. This leads to improvements in customer experience for tens of millions of people as well as operational benefits that can lead to substantial saving for the business.

LabSynch (medical research sharing) Business intelligence is demonstrated by enabling biomedical researchers and their colleagues to record, store and analyze massive volumes of useful study data with less effort while sharing methodology and data completely, rapidly, and in context.

Conference Chair Tom Clancy, Director of the San Diego Software Industry Council and Managing Director at Tao Venture Partners said We are very excited to be showcasing many of the new and innovative analytics applications being developed in the San Diego region. It is designed to educate business and the general public about the significant roles and possibilities analytics present for creating a healthier, safer and more efficient world.

About the Author:
The San Diego Software Industry Council is one of San Diego’s largest trade organizations for regional software companies, related technologies and services. More information about predictive analytics, bioinformatics, and business intelligence can be found at www.supermathconference.com

Methods – Sixty-two consecutive patients with DMPM underwent cytoreduction and perioperative intraperitoneal chemotherapy at the Washington Cancer Institute. Twenty-six clinical, radiological and histopathological parameters were analyzed in univariate and multivariate analyses using overall survival as an endpoint. Results – The overall survival was 79 months (range 1143 months), with 1-, 3- and 5-year survival rates of 84%, 58% and 50%, respectively. The following 14 prognostic variables were significant for survival in the univariate analysis: gender (P = .045), peritoneal cancer index (P = .038), completeness of cytoreduction score (P = .010), interpretive CT findings of the small bowel and mesentery (P = .001), mesothelioma cell type (P < .001), mesothelioma nuclear size (P < .001), nuclear/cytoplasmic ratio (P < .001), mitotic count (P < .001), atypical mitosis (P < .001), chromatin pattern (P < .001), cellular necrosis (P < .001), perineural invasion (P = .037), stroma pattern (P < .001) and depth of invasion (P = .014). In the multivariate analysis, the only factor that was independently associated with an improved survival after cytoreduction and perioperative intraperitoneal chemotherapy was mesothelioma nuclear size.

Conclusions – Mesothelioma nuclear size was the dominant factor determining overall survival in patients with DMPM. A histopathological staging system based on measurement of the nuclear size was proposed.

Another interesting study is called, HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. By A D Kennedy, G King, K M Kerr J Clin Pathol 1997;50:859-862. Here is an excerpt: Abstract – AIMS: To determine the usefulness of antibodies HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of the pleura. METHODS: Using microwave antigen retrieval and streptavidin-biotin complex horseradish peroxidase immunohistochemistry the above antibodies were used to stain sections of 57 malignant mesotheliomas, 17 reactive pleural hyperplasias, 23 cases of carcinoma metastatic in pleura, 20 primary ovarian cell carcinomas, and 20 primary renal cell carcinomas. RESULTS: Eighty six per cent of mesotheliomas and 82% of reactive mesothelial hyperplasias stained strongly with HBME-1. However, 48% of carcinomas metastatic to pleura also stained, as did all serous ovarian carcinomas. Seventy two per cent of mesotheliomas and 24% of reactive mesothelial hyperplasias stained strongly with the antithrombomodulin antibody; 86% and 88%, respectively, of these cases showed staining of any type. While 26% of metastatic carcinomas showed some staining with antithrombomodulin, only one third of these (9%) showed strong, yet focal, staining. Of 40 ovarian and renal carcinomas only two (5%) showed any staining with antithrombomodulin. CONCLUSIONS: HBME-1, although a sensitive mesothelial marker, is not sufficiently specific to be useful diagnostically, as almost half of carcinomas metastatic to pleura also stained positive. Antithrombomodulin is also a sensitive mesothelial marker and is sufficiently specific to be a useful discriminator, positively identifying, in appropriate circumstances, the mesothelial nature of a cell population.

Another interesting study is called, Malignant Pleural Mesothelioma: Surgical Roles and Novel Therapies – Clinical Lung Cancer – Volume 3, Number 2 / November 2001. Here is an excerpt: Abstract – Malignant pleural mesothelioma (MPM) is a uniformly fatal disease that has been recalcitrant to curative therapies. Median survivals of 8-18 months have, for the most part, led to a sense of frustration and nihilism in the medical and surgical community with regard to management of the disease, and the relatively small numbers of patients with mesothelioma have made it an orphan among other cancers with regard to research efforts and funding. This review will comment on the clinical presentation of the disease and therapeutic options that are available at this time. The role, timing, degree, and availability of cytoreductive surgery in the context of a multimodality approach for MPM will be highlighted, and various strategies that incorporate adjunctive therapies before, during, or after the operation will be discussed. Newer cytotoxic chemotherapies, either alone or in combination, are reviewed, with an emphasis on the increasing number of options with increased response rates that are becoming available for MPM patients. The results of protocols at selected centers that offer gene therapy, photodynamic therapy, hyperthermic chemotherapeutic perfusion, and intrapleural chemokines will be discussed, as well as newer preclinical approaches that base targeted therapies on novel molecular findings. In considering the newest approaches to the disease, one is encouraged to seek specialty consultation at centers that concentrate programmatic efforts on mesothelioma in order to design translational-based approaches on preclinical findings. By using such an approach, the patient and physician will find that there are considerably more options in the new century for mesothelioma.

About the Author:
Monty Wrobleski is the author of this article. For more information please click on the following links

Depuy Hip Recall Attorney

Depuy ASR Recall

Depuy Hip Recall